US5073379A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Continuous preparation of solid pharmaceutical forms
Assignee: BASF SE
•
Filing: 1989-08-25
•
Granted: 1991-12-17
•
Expires: 2009-08-25
Abstract
Abstract A mixture of one or more pharmaceutical active compounds and one or more thermoplastic polymers is tabletted by a process in which the mixture is extruded and the still moldable extrudate is pressed to give tablets, between two belts, or a belt and a roller, which make contact in parts, rotate in opposite directions and run parallel along the contact zone, the shape-imparting indentations, which may be present in complementary pairs, being located in both or in only one of the revolving shape-imparting elements.
Inventors
- 👤 Roger Klimesch
- 👤 Gerhard Bleckmann
- 👤 Karl-Peter Farwerck
- 👤 Lothar Schlemmer
- 👤 Axel Sanner
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 17:03
CPC Classifications
B; B30; B30B; B30B11/00; B30B11/02; B30B11/14; A; A61; A61J; A61J3/00; A61J3/10; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2027; A61K9/2095; B30B11/16; A61J2200/00; A61J2200/20
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
150 words
A process for tabletting a mixture of one or more pharmaceutical active compounds, one or more pharmacologically acceptable thermoplastic polymers, said polymers having a Fikentscher K value of from 10 to 100, and optional pharmaceutical auxiliaries, said mixture having a glass transition temperature below the decomposition temperature of all components of said mixture wherein said mixture is heated, without thermal and/or oxidative degradation, at a temperature of from 50° to 180° to render the mixture extrudable and said heated mixture is extruded at from 50° to 180° and the still formable extrudate is pressed between two belts or a belt and a roller to give tablets, said two belts or said belt and a roller making contact in parts, rotating in opposite directions and running parallel along a contact zone, at least one of said two belts or at least one of said belt and a roller having shape-imparting indentations.
Claim 2
Dependent Claim
150 words
A process for tabletting a mixture of one or more pharmaceutical active compounds, one or more pharmacologically acceptable thermoplastic polymers, said polymers having a Fikentscher K value of from 10 to 100, and optional pharmaceutical auxiliaries, said mixture having a glass transition temperature below the decomposition temperature of all components of said mixture wherein said mixture is heated, without thermal and/or oxidative degradation, at a temperature of from 50° to 180° to render the mixture extrudable and said heated mixture is extruded at from 50° to 180° and the still formable extrudate is pressed between two belts or a belt and a roller to give tablets, said two belts or said belt and a roller making contact in parts, rotating in opposite directions and running parallel along a contact zone, at least one of said two belts or at least one of said belt and a roller having shape-imparting indentations.
Claim 3
Dependent Claim
27 words
A process as claimed in claim 1, wherein two resilient belts having indentations which are opposite one another and, in pairs, determine the tablet shape are used.
Claim 4
Dependent Claim
22 words
A process as claimed in claim 1, wherein two metal link belts which contain the shape-imparting indentations in corresponding pairs are used.
Claim 5
Dependent Claim
47 words
A process as claimed in claim 1, wherein a rotating roller having shape-imparting indentations engraved on the lateral surface of the roller is used together with a smooth belt which rests against a segment of the lateral surface of the roller and revolves with the said surface.
Claim 6
Dependent Claim
19 words
A process as claimed in claim 4, wherein the revolving, smooth belt is replaced by a stationary, smooth wall.
Claim 7
Dependent Claim
28 words
A process as claimed in claim 1, wherein a rotating smooth roller is used together with a resilient belt which has the shape-imparting indentations in the contact surface.
Claim 8
Dependent Claim
42 words
A process as claimed in claim 2, wherein, instead of the second belt, a roller which rotates synchronously in contact with the first belt and on whose lateral surface engraved shape-imparting indentations correspond in pairs with those of the belt is used.
Claim 9
Dependent Claim
53 words
A process as claimed in claim 1, wherein the thermoplastic polymer used is a solvent-free N-vinylpyrrolidone polymer which has a water content of not more than 3.5% by weight and contains not less than 20% by weight of N-vinylpyrrolid-2-one (NVP) as copolymerized units, all comonomers which may be copolymerized containing nitrogen and/or oxygen.
Claim 10
Dependent Claim
24 words
A process as claimed in claim 8, wherein the thermoplastic polymer used contains not less than 60% by weight of NVP as copolymerized units.
Claim 11
Dependent Claim
27 words
A process as claimed in claim 8, wherein the thermoplastic polymer used consists of polyvinylpyrrolidone or contains only vinyl acetate as copolymerized units in addition to NVP.
Claim 12
Dependent Claim
65 words
A process as claimed in claim 8, wherein a thermoplastic polymer is used whose comonomers are selected from the following group: acrylic acid, methacrylic acid, crotonic acid, maleic acid (anhydride), itaconic acid (anhydride), esters of the stated acids or halfesters of the stated dicarboxylic acids with alcohols of 1 to 12 carbon atoms, hydroxyethyl and hydroxypropyl acrylate and methacrylate, acrylamide, methacrylamide, N-vinylcaprolactam and vinyl propionate.
Claim 13
Dependent Claim
32 words
A process as claimed in claim 8, wherein the thermoplastic polymer used is an NVP polymer which has been prepared either in an organic solvent or using an organic peroxide in water.
Claim 14
Dependent Claim
22 words
A process as claimed in claim 8, wherein not more than 20% by weight, based on the polymer, of plasticizers are used.
Claim 15
Dependent Claim
46 words
A process as claimed in claim 1, wherein the active compound used is one which is sparingly soluble in water, forms a molecular disperse phase in the polymer melt without the addition of solvents or water and forms a solid solution after solidification of the melt.
Claim 16
Dependent Claim
91 words
A process as claimed in claim 14, wherein one or more active compounds from the following group are used: acetaminophen (=paracetamol), acetohexamide, acetyldigoxin, acetylsalicylic acid, acromycin, anipamil, benzocaine, β-carotene, chloramphenicol, chlordiazepoxide, chlormadinone acetate, chlorothiazide, cinnarizine, clonazepam, codeine, dexamethasone, diazepam, dircumarol, digitoxin, digoxin, dihydroergotamine, drotaverine, flunitrazepam, furosemide, gramicidin, griseofulvin, hexobarbital, hydrochlorothiazide, hydrocortisone, hydroflumethiazide, indomethacin, ketoprofen, lonetil, medazepam, mefruside, methandrostenolone, methylprednisolone, methylsulfadiazine (=sulfaperin), nalidixic acid, nifedipine, nitrazepam, nitrofurantoin, nystatin, estradiol, papaverine, phenacetin, phenobarbital, phenylbutrazone, phenytoin, prednisone, reserpine, spironolactone, streptomycin, sulfadimidine(=sulfamethazine), sulfamethizole, sulfamethoxazole, sulfamethoxydiazine (=sulfameter), sulfaperin sulfathiazole, sulfisoxazole, testosterone, tolazamide, tolbutamide, trimethoprim and tyrothricin.
Claim 17
Dependent Claim
23 words
A process as claimed in claim 1, wherein an NVP polymer having a Fikentscher K value of from 10 to 50 is used.
Claim 18
Dependent Claim
23 words
A process as claimed in claim 1, wherein an NVP polymer having a Fikentscher K value of from 12 to 35 is used.
Claim 19
Dependent Claim
21 words
A process as claimed in claim 1, wherein said mixture is heated at a temperature of from 60 to 130° C.
Claim 20
Dependent Claim
19 words
A process as claimed in claim 1, wherein said mixture has a glass transition temperature less than 180° C.
Claim 21
Dependent Claim
19 words
A process as claimed in claim 19, wherein said mixture has a glass transition temperature less than 130° C.
References Cited (Backward Citations)
GB128409A
Cited
GB640440A
Cited
US2829756A
Cited
US3089818A
Cited
US3432592A
Cited
US4072551A
Cited
US4349531A
Cited
US4661521A
Cited
US4631284A
Cited
EP0240904B1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-12-16 | 1995-06-17 | 1995-12-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-12-16 | 1999-06-17 | 1999-12-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-12-16 | 2003-06-17 | 2003-12-17 | $7700.00 | Window Closed / Lapsed |